Elaine K. Sorg - 18 Feb 2026 Form 4 Insider Report for Artiva Biotherapeutics, Inc. (ARTV)

Reporting relationship: Director
Issuer ticker: ARTV
Reported as of: 18 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Feb 2026, 21:50:03 UTC
Prior SEC filing: 27 Apr 2023
Source filing: View source filing
Reporting owner signature: /s/ Andrew Cronauer, Attorney-in-Fact

Key filing fact

Elaine K. Sorg filed Form 4 for Artiva Biotherapeutics, Inc. (ARTV) on 19 Feb 2026.

Key facts

This page summarizes Elaine K. Sorg's Form 4 filing for Artiva Biotherapeutics, Inc. (ARTV).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 19 Feb 2026, 21:50.

Change

Previous filing in this sequence was filed on 27 Apr 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001832571 Primary reporting owner

Sorg Elaine K.

Relationship: Director
Address: C/O ARTIVA BIOTHERAPEUTICS, INC., 5505 MOREHOUSE DRIVE, SUITE 100, SAN DIEGO
Signature: /s/ Andrew Cronauer, Attorney-in-Fact
Signature date: 19 Feb 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ARTV transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +27,500
Change %
Price: $0.000000
Shares after: 27,500
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,500
Exercise price: $4.15
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One-third of the shares vested following the grant date, with the remaining shares vesting monthly over an additional two years following February 18, 2026.